BPC-157 US import rules: the FDA position

The short answer: BPC-157 has no FDA approval, no approved supply route, and no legal basis for personal importation for human use. Whether a parcel clears customs is a separate question from whether the import is lawful. This article covers what the primary US regulatory sources actually say, what has changed in the compounding landscape in 2026, and what the border picture looks like in practice.

FDA approval status: no NDA, no BLA, no approved product

BPC-157 is not an FDA-approved drug. No new-drug application (NDA) and no biologics licence application (BLA) has been submitted for BPC-157. No completed phase-2 or phase-3 randomised controlled trial in humans underpins either pathway^[1]. A 2026 review in Pharmaceutics found no approved formulation, no validated dosing regimen, and fewer than 30 subjects across three uncontrolled pilot studies in the entire human literature^[6]. The US Anti-Doping Agency states plainly that 'there appears to be no legal basis for selling BPC-157 as a drug, food, or a dietary supplement'^[2].

That absence of approval is not a technicality. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), a new drug may not be introduced into interstate commerce without FDA approval. BPC-157 meets the statutory definition of a new drug: it is not generally recognised as safe and effective for any use. Vendors who ship it for human consumption are not complying with that framework, regardless of whether they label the product 'for research use only.'

The compounding history: Category 2 and what happened in 2026

Section 503A of the FD&C Act allows licensed compounding pharmacies to prepare drugs from bulk substances, subject to FDA-defined conditions. The FDA maintains a list of bulk drug substances eligible for 503A compounding. Substances nominated for that list are placed into categories while under review: Category 1 (nominated, eligible for compounding pending a final rule), Category 2 (nominated but presenting safety or clinical concerns that preclude compounding), and Category 3 (withdrawn or never formally nominated).^[3]

In 2023, the FDA placed BPC-157 on Category 2. Category 2 placement meant that 503A compounding pharmacies could not prepare BPC-157 while that designation held. The FDA's grounds were that BPC-157 presented safety risks and lacked the evidence base to support compounding^[2]. The USADA page on BPC-157 notes that at the time the FDA 'confirmed there is also no legal basis for compounding pharmacies to use BPC-157 in compounded medications.'

On 15 April 2026, the FDA removed BPC-157 from Category 2 after the original nominators formally withdrew their nominations^[3]. That removal does not make BPC-157 legal to compound. It creates a gap: BPC-157 is no longer explicitly blocked under Category 2, but it is also not on the Category 1 positive list. For 503A pharmacies, the practical enforcement risk of dispensing BPC-157 under prescription remains essentially unchanged until the FDA completes its rulemaking.

The next inflection point is the Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for 23 to 24 July 2026 at the FDA's White Oak Campus in Silver Spring, Maryland. The committee is expected to consider whether BPC-157 (free base and acetate forms) should be added to the 503A positive list. The PCAC vote is advisory. Final authority rests with the FDA, and any formal rulemaking would follow on a separate timeline. Until that process concludes, BPC-157 remains an unapproved new drug under federal law.

Personal importation: the FDA's enforcement framework

The FD&C Act prohibits importing unapproved new drugs into the US. That prohibition applies to personal imports as well as commercial ones. The FDA does not publish a blanket personal-import exemption for unapproved drugs. What it does maintain is a policy of enforcement discretion: in certain circumstances, FDA officers may choose not to pursue enforcement action for small quantities of a drug imported for personal use. That discretion is not a right, and it does not apply uniformly to unapproved new drugs.

The conditions under which the FDA has historically applied enforcement discretion for personal drug imports are narrow: the drug must be for the individual's personal use (not for distribution), the quantity must be a small amount (typically considered a 90-day supply), the individual must not present a commercialisation risk, and the drug must not raise an immediate health risk to the public. None of these conditions changes whether the import is lawful. They describe circumstances in which the FDA may elect not to act, not circumstances in which the law permits the import.

For BPC-157, the FDA's own assessment is that the compound presents safety concerns. The OPSS advisory, citing the FDA directly, notes that the agency 'has cautioned against compounded versions due to safety risks and potential contamination with other substances.'^[1] A substance the FDA identifies as presenting safety risks is less likely to benefit from enforcement discretion than a well-characterised drug imported for an established condition.

What happens at the border

US Customs and Border Protection (CBP) works alongside the FDA and DEA at ports of entry. When a parcel containing an unapproved drug is intercepted, the typical outcome is one of three things: the shipment is detained pending FDA review, it is refused admission and returned to the sender, or it is seized without return. The 'for research use only' label on BPC-157 vials does not provide a customs clearance pathway. Research chemicals are not a recognised import category that bypasses FD&C Act requirements.

In practice, many parcels get through. International mail volume is large, and screening is not exhaustive. That practical reality is not an endorsement of the activity. Seizure rates are inconsistent, not zero, and the regulatory risk profile is not the same as the empirical seizure rate. Buyers who are intercepted face the loss of the shipment. Vendors who operate at commercial scale face a higher bar: FDA warning letters, import alerts, and potential criminal referral under 21 U.S.C. § 331 (prohibited acts under the FD&C Act).

The FDA has issued warning letters to vendors of unapproved peptides, including BPC-157. Warning letters are publicly posted and constitute notice that the vendor is operating outside the law. Repeated non-compliance can escalate to injunctions or criminal referral. The warning-letter record signals the FDA's enforcement posture toward the grey market, even when individual parcel interceptions are not consistent.

Athletes and military: a separate prohibition layer

For athletes subject to the WADA Code, the import question sits alongside a separate and categorical prohibition. BPC-157 is listed on the WADA Prohibited List under S0 (Non-Approved Substances), which covers any pharmacological substance not currently approved for human therapeutic use by any government health authority^[4]. The prohibition applies in competition and out of competition. There is no therapeutic use exemption pathway for BPC-157, because TUEs require an approved therapeutic indication.

USADA enforces the WADA Code for US athletes in Olympic and Paralympic sport. Speed skater Kamryn Lute received a one-year sanction in 2024 after voluntarily declaring BPC-157 use, despite never testing positive^[2]. Triathlete Anthony McCauley received a four-year sanction in 2025 after a whistleblower-initiated investigation found he had used and socially promoted multiple prohibited peptides including BPC-157^[2]. These cases confirm that testing is not the only enforcement mechanism.

For US military personnel, the US Department of Defense's Operation Supplement Safety programme classifies BPC-157 as both a prohibited dietary supplement ingredient and an unapproved drug^[1]. Service members are subject to strict-liability rules: intent or ignorance does not mitigate a positive result or confirmed use.

The grey market's reach does not make it lawful

BPC-157 is not scheduled as a controlled substance under the Controlled Substances Act. Simple possession for personal use is therefore not a drug-scheduling offence in the same way that possession of a Schedule II or III substance is. That distinction is real but often overstated. The enforcement gap between 'not criminalised at the possession level' and 'legal to import or use for human purposes' is wide. Sale, distribution, and importation for human use are prohibited under the FD&C Act without approval, and that prohibition is not the same as a controlled-substance scheduling.

A 2026 review in Sports Medicine concluded that 'many unapproved peptides demonstrate favorable tissue repair and metabolic outcomes in animal models, but rigorous human safety data are scarce'^[5]. BPC-157 is a named example. The animal literature is extensive; the human evidence for both efficacy and safety is thin. The combination of an unresolved safety profile and no approved clinical indication is what places BPC-157 in the category of substances for which the FDA's enforcement posture is active rather than passive.

For the full evidence and safety picture, see the BPC-157 peptide page and the US regulation hub. If you are considering BPC-157 for any health reason, the right conversation is with a clinician who knows your history, not with a vendor selling products outside the regulatory framework.